Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$23.96 USD
+0.12 (0.50%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $23.96 0.00 (0.00%) 6:16 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BEAM 23.96 +0.12(0.50%)
Will BEAM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BEAM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BEAM
Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?
Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study
BEAM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?
Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
Other News for BEAM
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
Wells Fargo Sticks to Their Buy Rating for Beam Therapeutics (BEAM)
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
Beam Therapeutics announces dosing of first patient with BEAM-302
Beam Therapeutics Stock (NASDAQ:BEAM): The Future of Gene Editing?